Trial Profile
Treatment Access Protocol For Patients Previously Treated With Dacomitinib On A Clinical Trial In Japan
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 25 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2018 Planned End Date changed from 1 May 2019 to 31 May 2019.